Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses

Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL

(2013) James M. Murphy et al.   BIOCHEMICAL JOURNAL

A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties

(2013) James M. Murphy et al.   BIOCHEMICAL JOURNAL

New insights into the structure and function of the pseudokinase domain in JAK2

(2013) Olli Silvennoinen et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Techniques to examine nucleotide binding by pseudokinases: Table 1

(2013) Isabelle S. Lucet et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers

(2013) Stefan N. Constantinescu et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Regulation of Janus kinases by SOCS proteins

(2013) Nadia J. Kershaw et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism

(2013) James M. Murphy et al.   IMMUNITY

A low-background-intensity focusing small-angle X-ray scattering undulator beamline

(2013) Nigel M. Kirby et al.   JOURNAL OF APPLIED CRYSTALLOGRAPHY

Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases

(2013) Angela V Toms et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition

(2013) Nadia J Kershaw et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The biology and mechanism of action of suppressor of cytokine signaling 3

(2012) Jeffrey J. Babon et al.   GROWTH FACTORS

Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity

(2012) Jeffrey J. Babon et al.   IMMUNITY

Detection ofJAK2mutations in paraffin marrow biopsies by high resolution melting analysis: identification ofL611Salone and in cis withV617Fin polycythemia vera

(2012) Roberto H. Nussenzveig et al.   LEUKEMIA & LYMPHOMA

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

(2012) Priya Koppikar et al.   NATURE

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

(2012) Rajintha M Bandaranayake et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group

(2011) J. Zhang et al.   BLOOD

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

(2011) Daniela Ungureanu et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation

(2011) Arturo Sanz et al.   PLoS One

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice

(2010) S. P. Gorantla et al.   BLOOD

A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F)

(2009) Lequn Zhao et al.   BIOCHEMICAL JOURNAL

SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases

(2009) J. Elliott et al.   HAEMATOLOGICA

Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains

(2009) Neal K. Williams et al.   JOURNAL OF MOLECULAR BIOLOGY

SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis

(2009) R Chaligné et al.   LEUKEMIA

SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling

(2009) S Haan et al.   ONCOGENE

JAK mutations in high-risk childhood acute lymphoblastic leukemia

(2009) C. G. Mullighan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

(2008) G. Wernig et al.   BLOOD

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia

(2008) L. Kearney et al.   BLOOD

Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders

(2008) Daniela Capello et al.   BRITISH JOURNAL OF HAEMATOLOGY

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders

(2008) N. Fourouclas et al.   HAEMATOLOGICA

Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases

(2008) Luciana Teofili et al.   INTERNATIONAL JOURNAL OF CANCER

The SOCS Box Domain of SOCS3: Structure and Interaction with the ElonginBC-Cullin5 Ubiquitin Ligase

(2008) Jeffrey J. Babon et al.   JOURNAL OF MOLECULAR BIOLOGY

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

(2008) Dani Bercovich et al.   LANCET